Abiopharma

🔍 Prahm Jeremy (Executive)

Company: Finance of America Companies Inc. (FOA)

Report Date: 2026-04-01

Detailed Transactions and Holdings:

• Acquired 40,322 shares of Class A Common Stock (Direct)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 207,616.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 18,387 shares of Class A Common Stock at $16.6 per share (Direct)
  Date: 2026-04-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 189,229.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 66,667 shares of Class A Common Stock (Direct)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 255,896.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 30,401 shares of Class A Common Stock at $16.6 per share (Direct)
  Date: 2026-04-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 225,495.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 32,958 shares of Class A Common Stock (Direct)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 258,453.00 | transaction_form_type: 4 | Footnotes: F4
• Sold 15,029 shares of Class A Common Stock at $16.6 per share (Direct)
  Date: 2026-04-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 243,424.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 40,322 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1
• Sold 66,667 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 66,667.00 | transaction_form_type: 4 | Footnotes: F3, F3, F3
• Sold 32,958 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 65,916.00 | transaction_form_type: 4 | Footnotes: F4, F4, F4
• Acquired 87,209 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 87,209.00 | transaction_form_type: 4 | Footnotes: F5, F5, F5

Footnotes:

• F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A common stock ("Common Stock"). The RSUs will be settled in either Common Stock or cash (or a combination thereof) at the discretion of the Issuer's compensation committee.
• F2: Represents the withholding of shares of Common Stock for tax purposes in connection with the settlement of RSUs.
• F3: Each RSU represents a contingent right to receive one share of Common Stock. The RSUs will be settled in either Common Stock or cash (or a combination thereof) at the discretion of the Issuer's compensation committee. The remaining RSUs vest on the third anniversary of April 1, 2024, subject to the Reporting Person's continued employment.
• F4: Each RSU represents a contingent right to receive one share of Common Stock. The RSUs will be settled in either Common Stock or cash (or a combination thereof) at the discretion of the Issuer's compensation committee. The remaining RSUs vest on the second and third anniversaries of April 1, 2025, subject to the Reporting Person's continued employment.
• F5: Represents additional RSUs granted to the Reporting Person on April 1, 2026. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs will be settled in either Common Stock or cash (or a combination thereof) at the discretion of the Issuer's compensation committee. The RSUs shall vest in one-third increments upon the first, second and third anniversaries of the vesting reference date, April 1, 2026, subject to the Reporting Person's continued employment.